16 January, 2006: Antibody therapeutics company, EvoGenix Ltd (ASX: EGX), has released results on the successful scientific development of its product for the treatment of bone loss, called OVP (OPG Variant Protein). EvoGenix has successfully applied its optimisation technology, called EvoGeneTM, to produce a variant of a naturally occurring regulator protein, Osteoprotegerin (OPG). The OPG variant (previously described by the company under its internal number EGX-010) retains all of OPG’s ability to stop abnormal bone erosion and loss, but now lacks a secondary activity of OPG which was the potential to increase cancer incidence in treated patients. The results were presented at the annual CHI conference on Protein Engineering, held in San Diego, California on Friday 13 January, 2006.
And the market seems to like it.
EGX Price at posting:
0.0¢ Sentiment: None Disclosure: Held
